IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN

Journal of Neuroimmunology

Volumn 229, Issue 1-2, 2010, Pages 256-262

  Piepers, Sanne ^a   Jansen, Marc D ^a   Cats, Elisabeth A ^a   van Sorge, Nina M ^a   van den Berg, Leonard H ^a   van der Pol, W Ludo ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti GM1 antibodies; Complement system; Immunoglobulins; IVIg; Multifocal motor neuropathy

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C4; GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN;

ADULT; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; COMPLEMENT BLOOD LEVEL; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; IN VITRO STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; G(M1) GANGLIOSIDE; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE;

EID: 78650227049     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.08.023     Document Type: Article

References (52)

1. Arasaki K., Kusunoki S., Kudo N., Tamaki M. The pattern of antiganglioside antibody reactivities producing myelinated nerve conduction block in vitro. J. Neurol. Sci. 1998, 161:163-168.
2. Azulay J.P., Rihet P., Pouget J., Cador F., Blin O., Boucraut J., Serratrice G. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J. Neurol. Neurosurg. Psychiatry 1997, 62:391-394.
3. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 1994, 94:1729-1735.
4. Bouche P., Moulonguet A., Younes-Chennoufi A.B., Adams D., Baumann N., Meininger V., Leger J.M., Said G. Multifocal motor neuropathy with conduction block: a study of 24 patients. J. Neurol. Neurosurg. Psychiatry 1995, 59:38-44.
5. Buchwald B., Ahangari R., Weishaupt A., Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann. Neurol. 2002, 51:673-680.
6. Carpo M., Cappellari A., Mora G., Pedotti R., Barbieri S., Scarlato G., Nobile-Orazio E. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998, 50:1480-1482.
7. Cats, E.A., Jacobs, B.C., Yuki, N. Tio-Gillen, A.P., Piepers, S., Franssen, H., Van Asseldonk, J.Th., Van den Berg, L.H., Van der Pol, W.L., in press. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features, Neurology.
8. Claus D., Specht S., Zieschang M. Plasmapheresis in multifocal motor neuropathy: a case report. J. Neurol. Neurosurg. Psychiatry 2000, 68:533-535.
9. Corbo M., Quattrini A., Latov N., Hays A.P. Localization of GM1 and Gal(beta 1-3)GalNAc antigenic determinants in peripheral nerve. Neurology 1993, 43:809-814.
10. Donaghy M., Mills K.R., Boniface S.J., Simmons J., Wright I., Gregson N., Jacobs J. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J. Neurol. Neurosurg. Psychiatry 1994, 57:778-783.
11. Gold R., Stangel M., Dalakas M.C. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 2007, 3:36-44.
12. Halstead S.K., O'Hanlon G.M., Humphreys P.D., Morrison D.B., Morgan B.P., Todd A.J., Plomp J.J., Willison H.J. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 2004, 127:2109-2123.
13. Halstead S.K., Humphreys P.D., Zitman F.M., Hamer J., Plomp J.J., Willison H.J. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J. Peripher. Nerv. Syst. 2008, 13:228-235.
14. Halstead S.K., Zitman F.M., Humphreys P.D., Greenshields K., Verschuuren J.J., Jacobs B.C., Rother R.P., Plomp J.J., Willison H.J. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008, 131:1197-1208.
15. Hughes P.R. 79(th) ENMC International Workshop: multifocal motor neuropathy. 14-15 April 2000, Hilversum, The Netherlands. Neuromuscul. Disord. 2001, 11:309-314.
16. Hughes R. The role of IVIg in autoimmune neuropathies: the latest evidence. J. Neurol. 2008, 255(Suppl 3):7-11.
17. Jacobs B.C., O'Hanlon G.M., Bullens R.W., Veitch J., Plomp J.J., Willison H.J. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003, 126:2220-2234.
18. Kabat E.A., Mayer M.M. Complement and complement fixation. Experimental immunochemistry 1967, 133-240. Charles C Thomas, Springfield, IL. E.A. Kabat, M.M. Mayer (Eds.).
19. Kuijf M.L., Van Doorn P.A., Tio-Gillen A.P., Geleijns K., Ang C.W., Hooijkaas H., Hop W.C., Jacobs B.C. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J. Neurol. Sci. 2005, 239:37-44.
20. Leger J.M., Chassande B., Musset L., Meininger V., Bouche P., Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001, 124:145-153.
21. Lopez P.H., Villa A.M., Sica R.E., Nores G.A. High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies. J. Neuroimmunol. 2002, 128:69-76.
22. Lutz H.U., Stammler P., Bianchi V., Trueb R.M., Hunziker T., Burger R., Jelezarova E., Spath P.J. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004, 103:465-472.
23. Mata S., Borsini W., Caldini A., De S.G., Piacentini S., Taiuti R. Long-term evolution of anti-ganglioside antibody levels in patient with chronic dysimmune neuropathy under IVIg therapy. J. Neuroimmunol. 2006, 181:141-144.
24. Meucci N., Cappellari A., Barbieri S., Scarlato G., Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry 1997, 63:765-769.
25. Nobile-Orazio E., Cappellari A., Meucci N., Carpo M., Terenghi F., Bersano A., Priori A., Barbieri S., Scarlato G. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J. Neurol. Neurosurg. Psychiatry 2002, 72:761-766.
26. Nobile-Orazio E., Cappellari A., Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005, 31:663-680.
27. O'Hanlon G.M., Paterson G.J., Wilson G., Doyle D., McHardie P., Willison H.J. Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system. J. Neuropathol. Exp. Neurol. 1996, 55:184-195.
28. O'Hanlon G.M., Plomp J.J., Chakrabarti M., Morrison I., Wagner E.R., Goodyear C.S., Yin X., Trapp B.D., Conner J., Molenaar P.C., Stewart S., Rowan E.G., Willison H.J. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001, 124:893-906.
29. Paparounas K., O'Hanlon G.M., O'Leary C.P., Rowan E.G., Willison H.J. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain 1999, 122(Pt 5):807-816.
30. Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 1998, 51:S22-S24.
31. Pestronk A., Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 1997, 49:1289-1292.
32. Pestronk A., Cornblath D.R., Ilyas A.A., Baba H., Quarles R.H., Griffin J.W., Alderson K., Adams R.N. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann. Neurol. 1988, 24:73-78.
33. Phongsisay V., Susuki K., Matsuno K., Yamahashi T., Okamoto S., Funakoshi K., Hirata K., Shinoda M., Yuki N. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J. Neuroimmunol. 2008, 205:101-104.
34. Roberts M., Willison H.J., Vincent A., Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann. Neurol. 1995, 38:111-118.
35. Santoro M., Uncini A., Corbo M., Staugaitis S.M., Thomas F.P., Hays A.P., Latov N. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann. Neurol. 1992, 31:385-390.
36. Susuki K., Rasband M.N., Tohyama K., Koibuchi K., Okamoto S., Funakoshi K., Hirata K., Baba H., Yuki N. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 2007, 27:3956-3967.
37. Taylor B.V., Gross L., Windebank A.J. The sensitivity and specificity of anti-GM1 antibody testing. Neurology 1996, 47:951-955.
38. Townson K., Boffey J., Nicholl D., Veitch J., Bundle D., Zhang P., Samain E., Antoine T., Bernardi A., Arosio D., Sonnino S., Isaacs N., Willison H.J. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology 2007, 17:294-303.
39. Uetz-von A.E., Sturzenegger M., Rieben R., Rihs F., Frauenfelder A., Nydegger U.E. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. Eur. Neurol. 1998, 39:103-110.
40. Umapathi T., Hughes R.A., Nobile-Orazio E., Leger J.M. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst. Rev. 2009, CD003217.
41. Uncini A., Santoro M., Corbo M., Lugaresi A., Latov N. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve 1993, 16:610-615.
42. Van den Berg L.H., Marrink J., de Jager A.E., de Jong H.J., van Imhoff G.W., Latov N., Sadiq S.A. Anti-GM1 antibodies in patients with Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 1992, 55:8-11.
43. Van den Berg L.H., Lokhorst H., Wokke J.H. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology 1997, 48:1135.
44. Van den Berg-Vos R.M., Franssen H., Wokke J.H., Van Es H.W., van den Berg L.H. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann. Neurol. 2000, 48:919-926.
45. Van Schaik I., Bossuyt P.M., Brand A., Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology 1995, 45:1570-1577.
46. Van Sorge N.M., van den Berg L.H., Geleijns K., van Strijp J.A., Jacobs B.C., Van Doorn P.A., Wokke J.H., van de Winkel J.G., Leusen J.H., van der Pol W.L. Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Ann. Neurol. 2003, 53:570-579.
47. Van Sorge N.M., van der Pol W.L., Jansen M.D., van den Berg L.H. Pathogenicity of anti-ganglioside antibodies in the Guillain-Barre syndrome. Autoimmun. Rev. 2004, 3:61-68.
48. Van Sorge N.M., Yuki N., Jansen M.D., Nishimoto Y., Susuki K., Wokke J.H., van de Winkel J.G., van den Berg L.H., van der Pol W.L. Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits. J. Neuroimmunol. 2007, 182:116-123.
49. Vucic S., Black K.R., Chong P.S., Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004, 63:1264-1269.
50. Willison H.J., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002, 125:2591-2625.
51. Willison H.J., Halstead S.K., Beveridge E., Zitman F.M., Greenshields K.N., Morgan B.P., Plomp J.J. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barre syndrome. J. Neuroimmunol. 2008, 201-202:172-182.
52. Yuki N., Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J. Neurol. Sci. 1996, 139:160-162.